Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Keynatinib in Treated Patients with NSCLC and Brain Metastases
Phase 2
Completed
- Conditions
- Non-Small Cell Lung Cancer with EGFR MutationBrain Metastases
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Medolution Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04824079
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Phase Ib Clinical Study of Keynatinib
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Medolution Ltd.
- Target Recruit Count
- 75
- Registration Number
- NCT04807881
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
News
No news found